US Patent

US8366600 — Polyamine enhanced formulations for triptan compound iontophoresis

Method of Use · Assigned to NuPathe Inc · Expires 2029-04-21 · 3y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a patch and compositions for iontophoresis of triptan compounds, such as sumatriptan succinate.

USPTO Abstract

A patch and compositions for iontophoresis of triptan compounds are described.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1327`	—	sumatriptan-succinate

Patent Metadata

Patent number: US8366600
Jurisdiction: US
Classification: Method of Use
Expires: 2029-04-21
Drug substance claim: No
Drug product claim: No
Assignee: NuPathe Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.